Abatacept

"Abatacept" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A fusion protein immunoconjugate of the extracellular domain of CTLA4 and the Fc domain of human IgG1. It functions as a T-cell co-stimulation blocker that inhibits TNF-ALPHA and prevents the activation of T-LYMPHOCYTES. It is used in the treatment of RHEUMATOID ARTHRITIS.

Descriptor ID	D000069594
MeSH Number(s)	D12.776.124.790.651.114.580.225 D12.776.377.715.548.114.580.225
Concept/Terms	Abatacept Abatacept LEA29Y LEA29Y BMS224818 BMS224818 BMS-224818 BMS 224818 Belatacept Belatacept Orencia Orencia BMS 188667 BMS 188667 BMS-188667 BMS188667 CTLA-4-Ig CTLA-4-Ig Cytotoxic T Lymphocyte-Associated Antigen 4-Immunoglobulin Cytotoxic T Lymphocyte Associated Antigen 4 Immunoglobulin CTLA4-Ig CTLA4-Ig Immunoconjugate CTLA4 Ig Immunoconjugate Immunoconjugate, CTLA4-Ig CTLA4-Fc Nulojix Nulojix

Below are MeSH descriptors whose meaning is more general than "Abatacept".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Serum Globulins [D12.776.124.790]
Immunoglobulins [D12.776.124.790.651]
Antibodies [D12.776.124.790.651.114]
Immunoconjugates [D12.776.124.790.651.114.580]
Abatacept [D12.776.124.790.651.114.580.225]
Globulins [D12.776.377]
Serum Globulins [D12.776.377.715]
Immunoglobulins [D12.776.377.715.548]
Antibodies [D12.776.377.715.548.114]
Immunoconjugates [D12.776.377.715.548.114.580]
Abatacept [D12.776.377.715.548.114.580.225]

Below are MeSH descriptors whose meaning is related to "Abatacept".

Below are MeSH descriptors whose meaning is more specific than "Abatacept".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Abatacept" by people in this website by year, and whether "Abatacept" was a major or minor topic of these publications.

Bar chart showing 32 publications over 17 distinct years, with a maximum of 4 publications in 2000 and 2002

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1994	0	1	1
1995	0	1	1
1996	0	2	2
1997	0	2	2
1998	0	3	3
1999	0	3	3
2000	0	4	4
2001	0	2	2
2002	0	4	4
2003	0	1	1
2004	0	1	1
2005	0	1	1
2006	0	2	2
2013	0	1	1
2016	1	0	1
2017	2	0	2
2018	0	1	1

Below are the most recent publications written about "Abatacept" by people in Profiles.

Uehara M, Solhjou Z, Banouni N, Kasinath V, Xiaqun Y, Dai L, Yilmam O, Yilmaz M, Ichimura T, Fiorina P, Martins PN, Ohori S, Guleria I, Maarouf OH, Tullius SG, McGrath MM, Abdi R. Ischemia augments alloimmune injury through IL-6-driven CD4+ alloreactivity. Sci Rep. 2018 02 06; 8(1):2461.

View in: PubMed
Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, Rosenblatt L, Rebello S, Kremer JM. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-? Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study. J Rheumatol. 2018 01; 45(1):32-39.

View in: PubMed
Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, Rosenblatt L, Rebello S, Kremer JM. A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice? Clin Rheumatol. 2017 Jun; 36(6):1215-1220.

View in: PubMed
Harrold LR, Reed GW, Solomon DH, Curtis JR, Liu M, Greenberg JD, Kremer JM. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry. Arthritis Res Ther. 2016 12 01; 18(1):280.

View in: PubMed
Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Greenberg JD. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis. 2015 Feb; 74(2):430-6.

View in: PubMed
Martin M, Kosinski M, Bjorner JB, Ware JE, Maclean R, Li T. Item response theory methods can improve the measurement of physical function by combining the modified health assessment questionnaire and the SF-36 physical function scale. Qual Life Res. 2007 May; 16(4):647-60.

View in: PubMed
Liu Q, Liu Z, Whitmire J, Alem F, Hamed H, Pesce J, Urban JF, Gause WC. IL-18 stimulates IL-13-mediated IFN-gamma-sensitive host resistance in vivo. Eur J Immunol. 2006 May; 36(5):1187-98.

View in: PubMed
Emery P, Kosinski M, Li T, Martin M, Williams GR, Becker JC, Blaisdell B, Ware JE, Birbara C, Russell AS. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J Rheumatol. 2006 Apr; 33(4):681-9.

View in: PubMed
Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005 Sep 15; 353(11):1114-23.

View in: PubMed
Fallarino F, Bianchi R, Orabona C, Vacca C, Belladonna ML, Fioretti MC, Serreze DV, Grohmann U, Puccetti P. CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med. 2004 Oct 18; 200(8):1051-62.

View in: PubMed

People

Explore

Similar Concepts

Top Journals